Skip to main content
Back to Corporate Site
Menu

Press Releases

Press release year list 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
December 14, 2020
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore
December 07, 2020
ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting
November 30, 2020
ADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62nd American Society of Hematology Annual Meeting
November 20, 2020
ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
November 12, 2020
ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights
November 10, 2020
ADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
November 05, 2020
ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020
November 04, 2020
ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting
November 03, 2020
ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors
October 30, 2020
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
October 09, 2020
ADC Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
September 23, 2020
ADC Therapeutics Announces Pricing of Public Offering
September 21, 2020
ADC Therapeutics Announces Proposed Public Offering
September 21, 2020
ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
September 17, 2020
ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020
September 10, 2020
ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers
September 04, 2020
ADC Therapeutics Gives Notice of Partial Waiver of Restrictions Pursuant to FINRA Rule 5131
August 18, 2020
ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights
August 12, 2020
ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020
July 17, 2020
ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib
July 06, 2020
ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine
June 12, 2020
ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
June 05, 2020
ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Being Presented at Virtual EHA Annual Congress
May 21, 2020
ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress
Download PDF format download (opens in new window)
May 19, 2020
ADC Therapeutics Announces Closing of Upsized $267 Million Initial Public Offering and Receipt of the $65 Million First Tranche under Its $115 Million Convertible Credit Facility with Deerfield
May 14, 2020
ADC Therapeutics Announces Pricing of Upsized Initial Public Offering
Download PDF format download (opens in new window)
May 11, 2020
ADC Therapeutics Announces Launch of Initial Public Offering
Download PDF format download (opens in new window)
May 01, 2020
ADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield
Download PDF format download (opens in new window)
April 27, 2020
ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of Directors
Download PDF format download (opens in new window)
April 24, 2020
ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering
Download PDF format download (opens in new window)
April 21, 2020
ADC Therapeutics Appoints Jennifer Creel as Chief Financial Officer
Download PDF format download (opens in new window)
March 19, 2020
ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company
Download PDF format download (opens in new window)
January 10, 2020
ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs
Download PDF format download (opens in new window)
January 09, 2020
ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Download PDF format download (opens in new window)